Micro-X gets FDA approval to market military X-Ray machine

Nanotube emitter X-Ray company Micro-X has received US Food and Drug Administration approval for its Rover lightweight X-Ray equipment (pictured) which is being marketed in the United States for use in field medical hospitals. Originally developed under contract to Australia’s defence department, the Rover is a ruggedised, military version of its Nano machine which generates…

Details

Bluglass installs commercial-scale semiconductor equipment at Silverwater plant

Semiconductor technology developer Bluglass has completed the installation of its largest-ever remote plasma vapour deposition (RPCVD) manufacturing system (main picture) at its Silverwater plant in Sydney. The commercial-scale system, known as BLG-500, is capable of creating 6×6 semiconductor wafers or 42 two inch wafers for the production of laser diodes, LED and microLED industries. It…

Details

Canberra to take the low road on electric vehicles

Comment by Peter Roberts The federal government appears likely to make no effort to support the establishment of electric vehicle manufacturing in Australia following the release of a new report. The report, funded by the Australian Renewable Energy Agency’s Advancing Renewables Programme, looked at the very low level of EV sales in Australia and decided…

Details

Monday news briefs – stories you might have missed

Respiri secures global sales and distribution agreement Asthma management system developer Respiri has signed an exclusive agreement with pharmaceutical firm Cipla to sell its Wheezo asthma management device. Cipla will initially market Wheezo in Australia and New Zealand, with further territories including the United States, Europe and India also on Cipla’s radar. Initial minimum sales…

Details

Recce Pharmaceuticals tests Covid treatment

Recce Pharmaceuticals will trial its anti-infective agents RECCE 327 and RECCE 529 against SARS- CoV-2. The company has teamed with North Carolina’s Path BioAnalytics to trial its broad-spectrum synthetic antibiotics which the company is commercialising to defeat resistant superbugs, Researchers at PBA will evaluate the company’s drug candidates in an ‘ex vivo respiratory organoid model…

Details